arrow
X

Xiaoqing Li

the no.1 central hospital of baoding
H指数:48
被引数:8,155

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and Safety of Firsekibart in Treatment of Active Systemic Juvenile Idiopathic Arthritis: A Randomized Phase 2 Study

Firsekibart治疗活动性系统性幼年特发性关节炎的疗效与安全性:一项随机二期研究

2026-03-110
OAAI
Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysis

基于介入治疗和免疫检查点抑制剂(ICIs)的组合方案在 intermediate- 和 advanced-stage 肝细胞癌患者中的比较疗效:一项系统评价、荟萃分析和网络荟萃分析

2026-02-070
OAAI
Redox-responsive chitosan hydrogel releases mitochondria-targeted fullerenol to reprogram M1/M2 macrophage balance for diabetic wound healing

氧化还原响应型壳聚糖水凝胶释放靶向线粒体的富勒醇,以重编程M1/M2巨噬细胞平衡用于糖尿病伤口愈合

2025-12-080
PRE
Cerebralcare Granule® restores intracranial lymphatic drainage system to support proactive brain health in Alzheimer’s disease models

Cerebralcare Granule® 恢复颅内淋巴引流系统,以支持阿尔茨海默病模型中的主动脑健康。

2025-11-260
PRE
SQLE drives bladder cancer progression by boosting mitochondrial oxidative phosphorylation

SQLE通过增强线粒体氧化磷酸化来驱动膀胱癌进展。

2025-11-180
OAAI
Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients

第三代酪氨酸激酶抑制剂Olverembatinib在复发及持续性微小残留病阳性费城染色体阳性急性淋巴细胞白血病患者中的有效性和安全性

2025-10-030
OAAI